Bimatoprost

Generic Name
Bimatoprost
Brand Names
Durysta, Latisse, Lumigan
Drug Type
Small Molecule
Chemical Formula
C25H37NO4
CAS Number
155206-00-1
Unique Ingredient Identifier
QXS94885MZ
Background

Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertensio...

Indication

Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.

Bimatoprost is also indicated to treat eyelash hypotrichosis.

Associated Conditions
Hypotrichosis of the eyelashes, Increased Intra Ocular Pressure (IOP)
Associated Therapies
-

Treatment of Hypopigmented Scars With Bimatoprost

First Posted Date
2023-11-08
Last Posted Date
2024-05-03
Lead Sponsor
Medstar Health Research Institute
Target Recruit Count
25
Registration Number
NCT06122090
Locations
🇺🇸

MedStar Washington Hospital Center, Washington, District of Columbia, United States

Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment

First Posted Date
2021-02-04
Last Posted Date
2022-08-05
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
4
Registration Number
NCT04738149
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

First Posted Date
2019-01-31
Last Posted Date
2023-11-21
Lead Sponsor
Laboratoires Thea
Target Recruit Count
485
Registration Number
NCT03825380
Locations
🇪🇪

Hospital, Tallinn, Estonia

A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension

First Posted Date
2016-04-19
Last Posted Date
2019-02-25
Lead Sponsor
ForSight Vision5, Inc.
Target Recruit Count
55
Registration Number
NCT02742649
Locations
🇵🇦

Clinica de Ojos Orillac - Calvo, Panama City, Panama

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2016-02-08
Last Posted Date
2017-03-17
Lead Sponsor
Allergan
Target Recruit Count
53
Registration Number
NCT02676310
Locations
🇺🇸

J&S Studies Inc., College Station, Texas, United States

🇺🇸

E&R Research Foundation, Lynchburg, Virginia, United States

🇺🇸

DermResearch, LLC, Austin, Texas, United States

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

First Posted Date
2015-09-01
Last Posted Date
2019-04-02
Lead Sponsor
ForSight Vision5, Inc.
Target Recruit Count
81
Registration Number
NCT02537015
Locations
🇺🇸

Sall Medical Research Center, Artesia, California, United States

🇺🇸

Total Eye Care, Memphis, Tennessee, United States

🇺🇸

Eye Research Foundation, Newport Beach, California, United States

and more 6 locations

Stop Retinal Ganglion Cell Dysfunction Study

First Posted Date
2015-03-17
Last Posted Date
2024-10-10
Lead Sponsor
University of Miami
Target Recruit Count
500
Registration Number
NCT02390284
Locations
🇺🇸

Bascom Palmer Eye Institute - University of Miami, Miami, Florida, United States

Dose-Ranging Study of the Bimatoprost Ocular Insert

First Posted Date
2015-02-09
Last Posted Date
2020-06-04
Lead Sponsor
ForSight Vision5, Inc.
Target Recruit Count
156
Registration Number
NCT02358369
Locations
🇺🇸

Vold Vision, Fayetteville, Arkansas, United States

🇺🇸

Total Eye Care, Memphis, Tennessee, United States

🇺🇸

University of Eye Specialists, Maryville, Tennessee, United States

and more 7 locations

Topical Bimatoprost Effect on Androgen Dependent Hair Follicles

First Posted Date
2014-06-23
Last Posted Date
2014-09-05
Lead Sponsor
Duke University
Target Recruit Count
33
Registration Number
NCT02170662

Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures

Phase 3
Completed
Conditions
Interventions
First Posted Date
2014-06-03
Last Posted Date
2014-06-03
Lead Sponsor
University of Milan
Target Recruit Count
200
Registration Number
NCT02154217
Locations
🇩🇪

Universitaets-augenklinik, Magdeburg, Germany

🇬🇷

Department of Ophthalmology, University of Thessaly, University Hos- pital of Larissa, Larissa, Greece

🇮🇹

A.O. San Paolo, Milan, Lombardy, Italy

and more 5 locations
© Copyright 2024. All Rights Reserved by MedPath